02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
00:29 , Oct 20, 2017 |  BC Week In Review  |  Company News

Syndax licenses menin-MLL inhibitors from Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
20:21 , Oct 17, 2017 |  BC Extra  |  Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
18:54 , Mar 17, 2017 |  BC Week In Review  |  Company News

Illumina, Munich Leukemia Laboratory, IBM deal

Munich Leukemia Laboratory (MLL) partnered with Illumina and IBM Watson to develop a Watson-based prototype to improve leukemia outcomes. IBM will provide its Watson cloud-based computing platform, which will MLL will use to analyze genomes...
19:14 , Jan 26, 2017 |  BC Innovations  |  Translation in Brief

Blanketly blocking MLL

Seven years after it discovered the unifying factor underlying the 70 seemingly unrelated translocations that all lead to mixed-lineage leukemia (MLL), a Northwestern team has devised a therapeutic strategy that could work across virtually all...
19:14 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia Cell culture and mouse studies suggest inhibiting IRAK4 could help treat mixed-lineage leukemia (MLL). In HEK cells, shRNA targeting IRAK4 or an IRAK4 inhibitor tool compound increased the stability of wild-type MLL1 ,...
19:40 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); leukemia Mouse studies suggest inhibiting MLL1 could help treat AML and other leukemias. In primary mouse bone marrow cells expressing a leukemogenic human fusion oncogene, knockdown of MLL1 decreased colony...
19:59 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest inhibiting ABL1 or its downstream effector MLL4 could help treat hepatic steatosis. In a mouse model of diet-induced hepatic steatosis, liver levels of ABL1 were higher than in normal...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-150 (miR-150); FMS-like tyrosine kinase 3 (FLT3; CD135); FMS-like tyrosine kinase 3 ligand (FLT3LG)

Cancer INDICATION: Acute myelogenous leukemia (AML); leukemia Patient sample, cell culture and mouse studies suggest miR-150 , a negative regulator of FLT3 , could help treat FLT3-driven AML and mixed lineage leukemia (MLL). miR-150 levels...